Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line
Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis’ Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line from Sygnis in the US and afterwards will provide the Caco-2 materials directly.
Partnership between BioNTech and Genentech to develop individualized mRNA cancer therapies
BioNTech has agreed to collaborate with Roche’s Genentech to develop and commercialize mRNA based, individualized cancer vaccines. The agreement will see the companies jointly develop individually tailored mRNA cancer vaccines applicable against a wide range of cancers, in a bid to potentially provide a new treatment paradigm for cancer patients.
Partnership between Zydus Cadila and Takeda to develop vaccine for Chikungunya virus
Zydus Cadila and Takeda Pharmaceutical have agreed to partner to develop a vaccine for an emerging infectious disease known as Chikungunya. The agreement will see both parties collaborating from an early stage development of the vaccine up to its final commercialization.
Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical to develop Regeneron’s Fasinumab
Regeneron and Teva entered a global agreement for the development and commercialization of the former’s NGF antibody, fasinumab. According to the developmental deal, Regeneron will receive payment of $250 million along with development and regulatory milestone payments, plus additional payments based on net sales. Regeneron will be responsible for the global development and commercialization of fasinumab in the U.S., and Teva will be responsible for the candidate’s development and commercialization outside the U.S.
Big Pharma companies including Cipla & Wockhardt in global alliance to fight drug resistance
13 global pharmaceutical companies have joined hands in laying out a roadmap to combat antimicrobial resistance (AMR) by 2020. The roadmap by these 13 drug firms follows the Industry Declaration signed in January 2016 at the World Economic Forum by more than 100 companies and trade associations, the companies said in a joint statement. The other companies in the alliance include global majors such as Johnson & Johnson, Novartis, Pfizer, Sanofi and AstraZeneca.